Serum levels of the adipokine FGF21 depend on renal function

  1. Sebastian Stein, MS1,
  2. Anette Bachmann, MD1,
  3. Ulrike Lössner, BS1,
  4. Jürgen Kratzsch, PhD2,
  5. Matthias Blüher, MD1,
  6. Michael Stumvoll, MD1 and
  7. Mathias Fasshauer, MD (mathias.fasshauer{at}medizin.uni-leipzig.de)1,3
  1. 1: University of Leipzig, Department of Internal Medicine III, 04103 Leipzig, Germany
  2. 2: University of Leipzig, Institute of Laboratory Medicine, 04103 Leipzig, Germany
  3. 3: Interdisciplinary Center for Clinical Research (IZKF) Leipzig, 04103 Leipzig, Germany

    Abstract

    Objective: To investigate renal elimination of the adipokine fibroblast growth factor 21 (FGF21) by determining circulating FGF21 levels in patients on chronic hemodialysis (CD) as compared to controls with a glomerular filtration rate (GFR) above 50 ml/min.

    Research Design and Methods: FGF21 was determined by ELISA in control (n=60) and CD (n=60) patients and correlated to clinical and biochemical measures of renal function, glucose and lipid metabolism, as well as inflammation, in both groups.

    Results: Median serum FGF21 levels were more than 15-fold higher in CD patients (3710.6 ng/l) as compared to subjects with a GFR above 50 ml/min (201.9 ng/l) (p < 0.001). Furthermore, serum creatinine positively and GFR negatively predicted FGF21 concentrations in multiple regression analyses in control subjects (p < 0.05).

    Conclusions: FGF21 serum levels increase in CD patients and are related to markers of renal function in controls.

    Footnotes

      • Received June 10, 2008.
      • Accepted September 24, 2008.

    This Article

    1. Published online before print October 7, 2008, doi: 10.2337/dc08-1054
    1. » Abstract
    2. Full Text (PDF)
    3. All Versions of this Article:
      1. dc08-1054v1
      2. 32/1/126most recent

    Current Issue

    1. December 2009, 32 (12)
    1. Current Issue
    1. Alert me to new issues of Diabetes Care